What’s next for the post-Gottlieb FDA
With the Trump administration putting out fires elsewhere, it could be a long temporary tenure for Dr. Scott Gottlieb’s acting replacement.
Most recent articles by Alison Kanski
Five things for pharma marketers to know: Friday, April 19, 2019
IBM halts Watson drug-development program; Most patients don’t think pharma has a good reputation; NIH awards $350 million for opioid research.
Watch: American Cancer Society reaches out to black consumers with star-studded ad
The push encourages people affected by cancer to take on a “boss” mentality when battling the disease.
New research gives mixed grades to employee wellness programs
Do wellness programs actually work? Yes and no, according to new research.
Johnson & Johnson profit down 14% in Q1
The company spent more than $400 million on litigation in the first quarter.
Five things for pharma marketers to know: Wednesday, April 17, 2019
UnitedHealth CEO wades into ‘Medicare for All’ debate; J&J’s Q1 earnings; Tennessee law limits attorney ads for drug lawsuits.
Having a heated debate about vaccines? Verywell’s new tool can help
Verywell wants to help people talk to others about vaccines without getting in a fight.
Survey: Patient influencers trust social media more than pharma websites
Wego Health also found that Facebook is influencers’ preferred network, despite privacy scandals.
Five things for pharma marketers to know: Monday, April 15, 2019
BMS shareholders approve Celgene deal; FDA warns public not to use apps to diagnose concussions; How the CDC could curb anti-vaxxers on social media.
AARP on its latest drug price campaign: ‘There’s a lot of anger out there’
The organization has fighting words for Big Pharma.
